Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
Status:
Terminated
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial will test the hypothesis that inhibition of c-kit signalling pathways in
pediatric patients with Neurofibromatosis Type I(NF-1) and progressing plexiform neurofibroma
will result in objective reduction and/or inhibition of plexiform neurofibromas progression.
This will be a Phase II study of imatinib mesylate given orally. Patients with stable or
responding disease may receive the drug for a period not exceeding one year.